Real-world study checks if immunotherapy combo extends life for aggressive lung cancer
NCT ID NCT05683977
First seen Nov 21, 2025 · Last updated May 06, 2026 · Updated 17 times
Summary
This study follows about 254 adults with extensive-stage small cell lung cancer who are getting durvalumab (an immunotherapy) plus standard chemotherapy as their first treatment. Researchers want to see how long patients stay on treatment and how long they live in real-world settings, outside of a controlled trial. The goal is to confirm that the benefits seen in earlier studies hold true for a broader, less selected group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Angers, 49933, France
-
Research Site
Argenteuil, 95107, France
-
Research Site
Avignon, 84000, France
-
Research Site
Avignon, 84918, France
-
Research Site
Bayonne, 64100, France
-
Research Site
Bordeaux, 33077, France
-
Research Site
Clermont-Ferrand, 63000, France
-
Research Site
Créteil, 94000, France
-
Research Site
Dijon, 21000, France
-
Research Site
Epagny Metz-Tessy, 74370, France
-
Research Site
Évreux, 27015, France
-
Research Site
Gleizé, 69400, France
-
Research Site
La Roche-sur-Yon, 85925, France
-
Research Site
La Rochelle, 17000, France
-
Research Site
Le Chesnay-Rocquencourt, 78150, France
-
Research Site
Limoges, 87000, France
-
Research Site
Marseille, 13008, France
-
Research Site
Nancy, 54100, France
-
Research Site
Nîmes, 30000, France
-
Research Site
Nîmes, 30900, France
-
Research Site
Osny, 95520, France
-
Research Site
Paris, 75005, France
-
Research Site
Pau, 64000, France
-
Research Site
Rennes, France
-
Research Site
Rouen, 76000, France
-
Research Site
Saint-Etienne, 42100, France
-
Research Site
Saint-Grégoire, 35760, France
-
Research Site
Saint-Quentin, 2321, France
-
Research Site
Toulon, 83000, France
-
Research Site
Toulouse, 31076, France
-
Research Site
Toulouse, 31400, France
-
Research Site
Valenciennes, 59300, France
-
Research Site
Vannes, 56017, France
-
Research Site
Villeurbanne, 69100, France
Conditions
Explore the condition pages connected to this study.